Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Burkitt Lymphoma 23Multiple Myeloma 21Lymphoma, Large B-Cell, Diffuse 21Leukemia, Myeloid, Acute 18Lymphoma, Non-Hodgkin 16Myelodysplastic Syndromes 15Lymphoma, B-Cell 14Lymphoma 14Recurrence 11Ovarian Neoplasms 11Lymphoma, Follicular 11Hodgkin Disease 11Triple Negative Breast Neoplasms 10Neoplasms 9Lymphoma, Mantle-Cell 9Leukemia, Lymphocytic, Chronic, B-Cell 9Breast Neoplasms 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Pancreatic Neoplasms 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia 8Hematologic Neoplasms 7Sarcoma 6Osteosarcoma 6Leukemia, Myelomonocytic, Chronic 6Colorectal Neoplasms 6Lymphoma, B-Cell, Marginal Zone 5Leukemia, Biphenotypic, Acute 5Graft vs Host Disease 5

Interventions

selpercatinib 1fludarabine 1aldesleukin 1Nivolumab 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × Cyclophosphamide × 30 days × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡